Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

FDA expands indication for Merck's Emend nausea and vomiting drug The US Food and Drug Administration (FDA) has approved the use of Merck's single-dose Emend (fosaprepitant dimeglumine) in combination with other antiemetic agents to prevent delayed nausea and vomiting in patients who receive moderately emetogenic chemotherapy (MEC). Regulatory Affairs > News
Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda Seattle Genetics will receive a one-time $20m milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
Contract Research & Services > Contract Services > News US FDA advisory committee votes in favor for Takeda and Lundbeck's Brintellix By PBR Staff Writer
The US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 to recommend the use of Brintellix (vortioxetine) to treat certain aspects of cognitive dysfunction in adults with major depressive disorder (MDD).
News Cancer Research UK starts phase 1/1b clinical trial of taladegib in combination with paclitaxel Ignyta announced that Cancer Research UK has initiated a new, investigator-sponsored Phase 1/1b clinical trial of a combination of paclitaxel with taladegib - the company's novel, orally available, hedgehog/smoothened inhibitor - in patients with platinum-resistant, recurrent ovarian cancer or recurrent, advanced solid tumors.
Contract Research & Services > Clinical Trials > News
Juventas enrolls first patient in phase 2 gene therapy clinical trial Juventas Therapeutics is enrolling its STOP-PAD trial, a 120-patient, placebo-controlled, randomized double-blinded Phase 2 study evaluating the safety and efficacy of JVS-100, a gene therapy encoding human stromal cell-derived factor-1 (SDF-1), in patients with advanced peripheral artery disease (PAD)
Contract Research & Services > Clinical Trials > News AAI/CML unveil new offering for solid state chemistry and formulation development AAIPharma Services Corp. / Cambridge Major Laboratories (AAI/CML) has announced today an integrated service offering for solid state chemistry and formulation development to help the pharma/biotech industry meet important milestones and maintain stability in drug development.
Automation > IT & Software > News Bavarian Nordic enters research partnership to develop MRSA vaccine By PBR Staff Writer
Bavarian Nordic has collaborated with Evaxion Biotech and Technical University of Denmark (DTU) to develop Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN) based vaccine against Methicillin-resistant Staphylococcus aureus (MRSA).
News

Latest News and Insight by Sector

Production & Manufacturing

Arch Biopartners submits AB569 orphan drug application to EMA
Arch Biopartners has submitted an application for orphan drug designation to the European Medicines Authority (EMA) for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
Production & Manufacturing > Process & Production > News
FDA issues complete response letter to Telesta's BLA for MCNA
The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Telesta Therapeutics' Biologics License Application (BLA) for MCNA.
Production & Manufacturing > Process & Production > News

Drug Research

Sigmoid Pharma agrees to acquire Freund Pharmatec
Sigmoid Pharma has entered into an agreement to acquire Freund Pharmatec.
Drug Research > Drug Delivery > News
ViaCyte acquires rights to BetaLogics assets from Janssen
ViaCyte and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have agreed to consolidate the assets of the Janssen BetaLogics group into ViaCyte.
Drug Research > Drug Delivery > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda
Seattle Genetics will receive a one-time $20m milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
Contract Research & Services > Contract Services > News
Cancer Research UK starts phase 1/1b clinical trial of taladegib in combination with paclitaxel
Ignyta announced that Cancer Research UK has initiated a new, investigator-sponsored Phase 1/1b clinical trial of a combination of paclitaxel with taladegib - the company's novel, orally available, hedgehog/smoothened inhibitor - in patients with platinum-resistant, recurrent ovarian cancer or recurrent, advanced solid tumors.
Contract Research & Services > Clinical Trials > News

Automation

AAI/CML unveil new offering for solid state chemistry and formulation development
AAIPharma Services Corp. / Cambridge Major Laboratories (AAI/CML) has announced today an integrated service offering for solid state chemistry and formulation development to help the pharma/biotech industry meet important milestones and maintain stability in drug development.
Automation > IT & Software > News
Panacea Pharmaceuticals selects Goodwin to develop anti-cancer monoclonal antibody
Panacea Pharmaceuticals has selected Goodwin Biotechnology to develop a proof-of-concept conjugation of a fully-human monoclonal antibody to a radionuclide chelator to generate an antibody-chelator conjugate.
Automation > IT & Software > News

Regulatory Affairs

US FDA advisory committee votes in favor for Takeda and Lundbeck's Brintellix
By PBR Staff Writer
The US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 to recommend the use of Brintellix (vortioxetine) to treat certain aspects of cognitive dysfunction in adults with major depressive disorder (MDD).
News
FDA expands indication for Merck's Emend nausea and vomiting drug
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved the use of Merck's single-dose Emend (fosaprepitant dimeglumine) in combination with other antiemetic agents to prevent delayed nausea and vomiting in patients who receive moderately emetogenic chemotherapy (MEC).
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery